ECM
HALO icon

Endurant Capital Management’s Halozyme HALO Stock Holding History

Endurant Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-115,500
Closed -$2.01M – 83
2017
Q3 		$2.01M Sell
115,500
-21,400
-16% -$290K 0.61% 55
2017
Q2 		$1.75M Sell
136,900
-39,200
-22% -$524K 0.5% 50
2017
Q1 		$2.28M Buy
+176,100
New +$2.23M 0.73% 40

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Endurant Capital Management's HALO Position: Q4 2017 in Review

Endurant Capital Management sold out of Halozyme (HALO) in Q4 2017, closing a stake of 115,500 shares — an estimated $2.01M sold.

Endurant Capital Management first reported a position in HALO in Q1 2017 and held it in 3 quarters. The position peaked at $2.28M in Q1 2017. 198 funds tracked by Wall St. Rank hold HALO as of Q4 2017.

  • Endurant Capital Management reported no remaining Halozyme position as of Q4 2017 after selling out during the quarter.
  • Endurant Capital Management sold 115,500 Halozyme shares in Q4 2017, an estimated $2.01M.
  • Endurant Capital Management first reported a position in Halozyme in Q1 2017 and held it in 3 quarters.
  • Endurant Capital Management's Halozyme position peaked at $2.28M in Q1 2017.
  • 198 funds tracked by Wall St. Rank held Halozyme as of Q4 2017.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.